The role of NMDAR antibody in the etiopathogenesis of schizophrenia

10Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Many authors have reported the presence of serum NMDAR antibodies in varying proportions of patients with schizophrenia; however, many others have not been able to confirm this. Because of the contradictory findings reported in various studies, more definitive research on this issue is required. Hence, we have investigated the NR1 subunit of NMDAR antibodies in patients with schizophrenia (n=49) and healthy controls (n=48). None of the investigated patients with schizophrenia and none of the healthy controls showed positive antibody against the NR1 subunit of the NMDAR. On the basis of this result, we conclude that the NR1 subunit of the NMDAR antibodies does not seem to have a role in schizophrenia.

Cite

CITATION STYLE

APA

Timucin, D., Ozdemir, O., & Parlak, M. (2016). The role of NMDAR antibody in the etiopathogenesis of schizophrenia. Neuropsychiatric Disease and Treatment, 12, 2327–2332. https://doi.org/10.2147/NDT.S113872

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free